Analysts Set Expectations for ARQT Q1 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Stock analysts at HC Wainwright issued their Q1 2027 earnings estimates for Arcutis Biotherapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of $0.08 per share for the quarter. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is $0.16 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q2 2027 earnings at $0.19 EPS, Q3 2027 earnings at $0.25 EPS and Q4 2027 earnings at $0.48 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05. The firm had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.93%.

A number of other brokerages also recently weighed in on ARQT. Needham & Company LLC boosted their price objective on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Morgan Stanley lifted their target price on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday. Guggenheim upped their target price on Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wall Street Zen upgraded Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $35.57.

Arcutis Biotherapeutics Trading Down 2.5%

Arcutis Biotherapeutics stock opened at $26.43 on Friday. Arcutis Biotherapeutics has a 1 year low of $13.69 and a 1 year high of $31.77. The firm’s 50-day moving average is $25.97 and its 200-day moving average is $24.69. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.46 and a current ratio of 2.68. The company has a market cap of $3.31 billion, a P/E ratio of 125.86 and a beta of 1.49.

Insider Activity

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 4,375 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the transaction, the insider directly owned 717,203 shares of the company’s stock, valued at $18,733,342.36. The trade was a 0.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Howard G. Welgus sold 4,096 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.41, for a total transaction of $99,983.36. Following the completion of the transaction, the director owned 38,378 shares of the company’s stock, valued at approximately $936,806.98. This trade represents a 9.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 16,894 shares of company stock worth $422,044 over the last ninety days. Insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. grew its holdings in Arcutis Biotherapeutics by 325.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after buying an additional 833 shares in the last quarter. Global Retirement Partners LLC bought a new stake in Arcutis Biotherapeutics during the 4th quarter valued at $35,000. EverSource Wealth Advisors LLC raised its stake in Arcutis Biotherapeutics by 124.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after acquiring an additional 698 shares in the last quarter. NewEdge Advisors LLC boosted its position in Arcutis Biotherapeutics by 209.0% during the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after acquiring an additional 1,045 shares during the period. Finally, Truvestments Capital LLC boosted its position in Arcutis Biotherapeutics by 114.2% during the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock worth $87,000 after acquiring an additional 1,606 shares during the period.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Needham raises price target: Needham & Company raised its price target on ARQT to $40 from $36 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. Benzinga analyst update
• Positive Sentiment: Strong Q2 results and higher guidance: Arcutis reported earnings of $0.11 per share, above estimates of $0.06-$0.09, while revenue of $129.9 million exceeded expectations of $118.9 million. Revenue increased 59% year over year and 23% sequentially, driven by demand for ZORYVE. Management raised 2026 net product sales guidance to $525 million-$540 million and reported positive operating cash flow. Arcutis second-quarter 2026 results
• Positive Sentiment: Additional ZORYVE growth opportunities: The FDA approved ZORYVE cream for plaque psoriasis in children as young as two. The FDA also accepted an application for infants with atopic dermatitis, with a decision expected by February 2027. Results from a Phase 2 vitiligo study are expected in the fourth quarter of 2026. Arcutis business update
• Neutral Sentiment: Routine insider selling: Three executives sold a combined 6,560 shares under pre-arranged Rule 10b5-1 plans to cover tax withholding tied to vested equity awards. Because the sales were administrative and represented less than 1% of each executive’s holdings, they provide limited evidence of bearish conviction. SEC insider trading filing

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.